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Dietary calcium intake was assessed using a validated, semi-quantitative food frequency questionnaire 123 (FFQ), which also includes portion size (21). This FFQ has been validated in the Geneva population 124
(22). 125
Plasma 25-hydroxyvitamin D levels were available for the majority of the participants (n=1204, 126 NU=582, PU=359, CU=263) from the second CoLaus visit that took place within 6 months before the 127
OsteoLaus visit. Plasma 25-hydroxyvitamin D level was measured using an ultra-high pressure liquid 128 chromatography-tandem mass spectrometry system (23). The inter-day CV% was 4.6% at 40 nmol/L. 129
Statistical analysis: Statistical analyses were conducted using Stata v14.1 (StataCorp, College Station, 130 Texas, USA) for windows. Descriptive results were expressed as number of participants (percentage) 131 or as average ± standard deviation. Bivariate analyses were conducted using chi-square for categorical 132 variables and analysis of variance for continuous variables. Multivariate analyses for continuous 133 variables were conducted using analysis of variance or multiple regression; results were expressed 134 either as adjusted average ± standard error or as slope and (95% confidence interval). Post-hoc 135 pairwise comparisons were performed using the method of Scheffe. The association between bone 136 outcomes and time since MHT discontinuation was modeled by nonlinear regression in order to 137 identify possible hinges in the relationship. For each bone parameter, the hinge and the slopes before 138 and after the hinge (when present) were estimated and their 95% confidence levels were assessed by 139 bootstrap with 100 replications. Statistical significance was considered for a bivariate test with a p-140 value <0.05. 141
RESULTS: 142
Of the 1279 women included in the analysis, 282 (22%) were CU, 380 (30%) were PU and 617 (48%) 143 were NU. The vast majority of participants were of Caucasian ethnicity (1256/1279, 98.2%). Their 144 baseline characteristics according to MHT group are shown in Table 1 . PU were significantly older, 145 had a higher prevalence of fractures, took more frequently calcium and vitamin D supplements and 146 had a higher 10-year fracture risk. The latter was no longer present after adjustment for age. No 147 differences were found for body mass index and dietary intake of calcium. There was a significant 148 difference regarding plasma 25-hydroxyvitamin D levels (CU>PU>NU), which however remained 149 slight with an average difference of 5.5 nmol/l between CU and NU. 150
The results for the primary bone outcomes according to MHT group, both unadjusted and after 151 adjustment for age and BMI are shown in Table 2 . CU had consistently higher values of TBS and 152 BMD at all sites compared with NU and PU in both unadjusted and adjusted models. After adjustment 153 for age and BMI, PU showed higher lumbar spine and total hip BMD than NU (p=0.017 and p=0.026 154 respectively). A trend in favor of PU versus NU was noted for TBS values (p=0.066). 155
The effect of MHT was also assessed by a multivariate analysis with age as an independent variable 156 (Table 3) . The adjusted slopes for 10-year increments showed a decrease of all sites BMD and TBS 157 loss according to MHT status: CU<PU<NU (p<0.05 for trend). group. CU exhibited significantly less steep slopes for loss of TBS as well as BMD at all sites. BMI-160 adjusted slopes for PU were significantly less steep than the ones for NU, with the exception of the 161 BMD at femoral neck. 162 Table 4 shows the bone parameters according to MHT duration and time since MHT withdrawal. No 163 association was found between MHT duration and bone outcomes in the combined CU+ PU group. In 164 PU, all BMD and TBS values were significantly higher when the time since discontinuation was less 165 than 2 years in comparison to more than 5 years. A multivariate regression analysis using time since 166 MHT discontinuation as a continuous variable led to similar conclusions, whereas a hinge analysis 167 (Table 5 ) allowed the identification of an inflexion point between 2 and 4 years since MHT 168 discontinuation, beyond which the benefit of MHT on bone outcomes has disappeared. No statistically 169 significant difference was noted between the different bone outcomes (TBS, BMD at different sites) 170 in terms of inflexion points. 171
DISCUSSION: 172
To maximize anti-fracture efficacy, agents against osteoporosis should ideally have an effect on both 173 bone mass and bone microarchitecture. TBS has emerged as a non-invasive, easily-acquired and8 reliable indirect indicator of bone microarchitecture, providing an additional surrogate marker for 175 fracture risk assessment (4). The effect of anti-osteoporotic drugs on TBS has been shown to be 176 smaller in magnitude than the one on BMD (4, 24). In a substudy of the randomized TEAM trial, 177
Kalder et al explored the effect of exemestane and tamoxifen on BMD and TBS in postmenopausal 178 women with hormone-sensitive breast cancer (25). After 2 years, TBS increased by 3.3% in the 179 tamoxifen group compared to a decrease of 2.3% in the exemestane group. The positive impact of 180 tamoxifen on TBS could suggest a potential advantage related with its estrogenic agonist properties. 181
This crossectional analysis of the OsteoLaus cohort demonstrates for the first time that MHT is 182 associated with higher levels of TBS. CU presented significantly higher TBS values than NU and PU. 183
After adjustment for age and BMI, a trend for higher TBS values in PU versus NU was observed. In 184 the multivariate analysis, slopes for 10-year increments were significantly less steep in both CU and 185 PU, indicating that MHT slows down the age-associated loss of TBS. Interestingly, the slopes for age-186 associated decline in TBS were significantly more pronounced than those in spine BMD, a finding 187 which was attributed to TBS being less influenced by age-induced osteoarthritic changes (4), which 188 falsely elevate spine BMD. 189
The only clinical study that has analyzed the effect of MHT on bone microarchitecture is the Kronos 190 in the early menopausal phase. After 3 years, those assigned to MHT regimens had an average gain of 202 5.1% and 2.4% at spine and total hip BMD respectively, compared to a loss of 2.8 and 2.2% in the 203 placebo group (28). In the relatively older population of the WHI trial (29), after 3 years of follow-up, 204 the percentage difference in favor of the MHT group was 4.5% and 3.6% for BMD at lumbar spine 205 and total hip respectively. MHT was effective despite the absence of osteoporosis at baseline (mean 206 T-scores: -1.3 at lumbar spine, -0.94 at total hip). 207
If the beneficial effect of MHT on BMD is well established, this is not the case for the BMD 208 preservation after its withdrawal. Our data argue in favor of a partially persistent effect in PU, who 209 showed higher BMD values in the age-adjusted analysis, as well as a less rapid decrease of age-210 associated BMD loss at lumbar spine and total hip compared to NU. Further analysis confirmed that 211 time since MHT withdrawal is a crucial factor, with early discontinuers (< 2 years) presenting with 212 significantly higher BMD levels than the late ones (> 5 years). The inflexion point, beyond which the 213 BMD benefit disappears, is estimated between 2-4 years. 214
Conflicting data exist about an eventual rebound effect after MHT withdrawal resulting in rapid loss 215 of the previously acquired benefit. Several non-randomized studies (30, 31, 32) did not find any 216 accelerated bone loss after MHT discontinuation. In the PERF study (30), the dosage of bone 217 remodeling markers did not show increased bone resorption following MHT withdrawal. However, in 218 a randomized placebo-controlled trial, Greenspal et al (33) revealed significant loss of BMD (4.5%, 219 2.4% and 1.8% at lumbar spine, femoral neck and total hip respectively) 1 year after estrogen 220 withdrawal in comparison to alendronate discontinuation in 425 hysterectomized women, previously 221 treated with these agents versus placebo for 2 years. The loss of BMD observed in the estrogen group 222 was associated with an increase of bone resorption markers. Similar results were described in other 223 trials of recently menopaused (34, 35) or older women (36). In the latter study, there were no 224 significant BMD differences between PU and placebo group already 2 years after estrogen 225
withdrawal. 226
Possible explanations for these divergent results can be hypothesized. In the PERF trial, the authors 227 reported heterogeneous rates of bone loss with faster decrease of BMD in women with lower BMI. Another interesting point is the between-sites discrepancy with absence of residual effect on femoral 240 neck, whose content is rich in cortical bone. This finding has not been reproduced in previous studies 241 and should be considered cautiously until further evaluation, given that estrogen-deprivation states 242 have been preferentially linked to loss of trabecular bone. 243 BMD and TBS are surrogate markers of osteoporotic fracture risk. Consequently, given our results in 244 favor of a residual effect in PU, we would expect decreased fracture incidence in this group in 245 comparison with NU. The recently published NICE guidelines (37) on the effect of MHT recency and 246 duration on fracture incidence support this hypothesis. Indeed, after an exhaustive meta-analysis and 247 based mostly on observational trials, the authors concluded that bone benefits of MHT seem to persist 248 after its withdrawal; however they have vanished by 5 years since MHT discontinuation. Data derived 249 from randomized controlled trials showed no effect of MHT duration on fracture risk, whereas some 250 observational studies suggested additional benefits only for MHT duration longer than 10 years. 251
In agreement with these conclusions, we did not detect any BMD differences according to MHT 252 duration in the combined CU+PU group. The most plausible explanation is the accelerated gain of 253 bone density at all sites during the first 2 years of treatment, seen with MHT (29) and also described 254 for other antiresorptives. The increase of bone density slows down during the next years of treatment 255 with a subsequent flattening of the changes, thus constituting the overall duration of MHT a less 256 decisive factor on bone outcomes. 257
Our study has several limitations. First, the beginning and the end of MHT were self-reported. 258
Second, for the same reason we could not reliably distinguish the different routes of administration of 259
MHT (oral, transdermal, vaginal) or the type of MHT (estrogen-alone or estrogen/progestin). Third, 260
we could not determine the dose of estrogen per participant, which can be important given the 261 potentially dose-dependent effects on bone outcomes. On the other hand, our study has many strong 262 points to be taken into account. The large sample of the OsteoLaus cohort allows for adequate 263 statistical power to detect differences between groups. Another strength is the quality of the data 264 collected in the cohorts CoLaus and OsteoLaus. Radiological tests were performed in high quality and 265 standardized devices allowing for accurate measurement of BMD and TBS. 266
In conclusion, we report herein for the first time that MHT is associated with better preservation of 267 bone microarchitecture, as assessed by TBS. In addition to the well-established positive effect of 268 MHT on BMD, the bone microarchitecture preservation probably contributes to the anti-fracture 269 efficacy. The protective effect of MHT on BMD and TBS seems to persist after its withdrawal for at 270 least 2 years. Given the renewed interest in MHT, our results provide encouraging informations for 271 the impact of this treatment and its withdrawal on bone health. 
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